Regulatory Reform: FDA Pushes Back, Asks For Specific Problems To Fix
Executive Summary
FDA pushed back against a growing number of calls for regulatory reform during the U.S. Conference on Rare Diseases and Orphan Products, mainly because they were just generalized complaints.
You may also be interested in...
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?
FDA may be able to talk in theoretical terms about the flexibility it is afforded for orphan products approvals, but others seem to want more tangible evidence. For its part, the agency wants more than general complaints about its regulations; it wants an open discussion of specific roadblocks.
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?
FDA may be able to talk in theoretical terms about the flexibility it is afforded for orphan products approvals, but others seem to want more tangible evidence. For its part, the agency wants more than general complaints about its regulations; it wants an open discussion of specific roadblocks.
Orphan Disclosures Could Increase Under Tweaks Proposed By FDA
Agency considering whether to tell public if sponsors have submitted annual product development reports as part of proposed rule clarifying portions of 1992 Orphan Drug Regulations.